• Revenue down 7% to $9.8 million
• Loss narrowed by 59.5% to $1.3 million
• Strong performance in API Manufacturing and Specialty Orals

IDT Australia Limited reported its financial results for the half-year ended 31 December 2025. Revenue from ordinary activities and other income was down 7.0% to $9.8 million, while the loss from ordinary activities after tax attributable to the owners narrowed by 59.5% to $1.3 million. The company's three key verticals performed as follows: Advanced Therapies revenue declined due to customer timing, but the vertical remains a focused area for strong growth; API Manufacturing grew 191.4% to $3 million, playing a key role in funnelling business to other verticals; and Specialty Orals revenue grew 26% to $2.5 million, with increased growth opportunities in radiopharmaceuticals. The company's cash position improved, with a closing cash balance of $1.9 million and an unused debt facility of $8.5 million, providing support for the company's strategic initiatives and manufacturing capabilities.